B. Riley initiated coverage of Oncology Institute (TOI) with a Buy rating and $6 price target The firm says Oncology Institute is one of the largest oncology specialty value-based healthcare service providers. The company’s recent debt facility amendment removed a key financial overhang on the shares, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOI:
- Oncology Institute names Kristin England chief administrative officer
- Oncology Institute to be exclusive oncology provider for SilverSummit Healthplan
- Oncology Institute files $50M common stock offering
- Oncology Institute management to meet virtually with B. Riley
- Oncology Institute to join Russell 2000, Russell 3000 indexes